Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Parallel-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated 2 Doses Inactivated SARS-CoV-2 Vaccine

NCT05428592 is registered in ClinicalTrials.gov with AIM Vaccine Co., Ltd. as lead sponsor.

NCT NCT05428592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05428592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Parallel-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated 2 Doses Inactivated SARS-CoV-2 Vaccine
Lead sponsor
AIM Vaccine Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2023
Completion date
October 31, 2024
Enrollment
1,100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2